Get the Stockscreener App
89.75
1.87%
1.65
After Hours:
89.75
Nuvalent Inc stock is traded at $89.75, with a volume of 418.87K.
It is up +1.87% in the last 24 hours and up +11.53% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$88.10
Open:
$88.2
24h Volume:
418.87K
Relative Volume:
0.96
Market Cap:
$5.98B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-23.01
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+7.04%
1M Performance:
+11.53%
6M Performance:
+35.39%
1Y Performance:
-13.36%
1-Day Range:
$87.11
$89.88
1-Week Range:
$82.00
$89.88
52-Week Range:
$55.53
$106.32
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
89.75 | 6.35B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent to present new data on HER2 inhibitor at cancer conference By Investing.com - Investing.com South Africa
Nuvalent to present new data on HER2 inhibitor at cancer conference - Investing.com Canada
Preclinical intracranial activity: Nuvalent’s NVL-330 to be presented at AACR‑NCI‑EORTC Oct 24 - Stock Titan
Will Nuvalent Inc. stock rally after Fed decisionsJuly 2025 Weekly Recap & Low Risk Investment Opportunities - newser.com
How Nuvalent Inc. stock reacts to oil pricesBond Market & Entry Point Confirmation Signals - newser.com
Statistical indicators supporting Nuvalent Inc.’s strengthShare Buyback & Verified Momentum Stock Watchlist - newser.com
What moving averages say about Nuvalent Inc.Trade Exit Summary & Weekly High Potential Stock Alerts - newser.com
Custom strategy builders for tracking Nuvalent Inc.Weekly Trade Review & Verified Short-Term Plans - newser.com
Forecasting Nuvalent Inc. price range with options data2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 32% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Regression analysis insights on Nuvalent Inc. performance2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Is Nuvalent Inc. stock bottoming outVolume Spike & Weekly Chart Analysis and Trade Guides - newser.com
Nuvalent (NASDAQ:NUVL) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Can trapped investors hope for a rebound in Nuvalent Inc.July 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
Nuvalent Inc. stock trendline breakdown2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Is Nuvalent Inc. showing signs of accumulationJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
What MACD signals say about Nuvalent Inc.Trade Entry Report & Risk Managed Investment Strategies - newser.com
Intraday pattern recognizer results for Nuvalent Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - newser.com
Is Nuvalent Inc. stock a buy before product launchesMarket Trend Review & Precise Buy Zone Tips - newser.com
The Escalator: Eli Lilly, Nuvalent, Lumen Bioscience and more - Medical Marketing and Media
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year - Investing.com
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating - 富途牛牛
What to expect from Nuvalent Inc. in the next 30 daysJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Will Nuvalent Inc. stock outperform Dow Jones index2025 Key Lessons & AI Driven Price Predictions - newser.com
Is Nuvalent Inc. reversing from oversold territoryQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
Analyzing net buyer seller activity in Nuvalent Inc.Quarterly Risk Review & Free Expert Approved Momentum Trade Ideas - newser.com
Nuvalent, Inc. Stock (NUVL) Opinions on Cancer Therapy Developments and Insider Sale - Quiver Quantitative
Nuvalent CFO Balcom sells $2.3m in NUVL stock By Investing.com - Investing.com Australia
Nuvalent chief development officer Noci sells $332k in shares By Investing.com - Investing.com Australia
Nuvalent chief development officer Noci sells $332k in shares - Investing.com India
Nuvalent CFO Balcom sells $2.3m in NUVL stock - Investing.com
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Balcom Alexandra | Chief Financial Officer |
Oct 01 '25 |
Sale |
85.48 |
20,000 |
1,709,512 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 30 '25 |
Option Exercise |
6.89 |
20,000 |
137,800 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 29 '25 |
Option Exercise |
6.89 |
7,588 |
52,281 |
69,322 |
| Balcom Alexandra | Chief Financial Officer |
Sep 30 '25 |
Sale |
85.06 |
20,000 |
1,701,200 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Sep 29 '25 |
Sale |
85.01 |
7,588 |
645,056 |
61,734 |
| Noci Darlene | Chief Development Officer |
Sep 29 '25 |
Option Exercise |
27.85 |
4,000 |
111,400 |
52,034 |
| Noci Darlene | Chief Development Officer |
Sep 29 '25 |
Sale |
83.07 |
4,000 |
332,288 |
48,034 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):